玻璃体内注射后局部应用萘非那酮：一项前瞻性双盲随机对照试验。
Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial.
作者信息
Ulrich J Niklas
机构信息
Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.
出版信息
Retina. 2014 Mar;34(3):509-11. doi: 10.1097/IAE.0b013e3182a0e611.
PURPOSE
To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo.
METHODS
One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.
RESULTS
Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).
CONCLUSION
A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.
目的
评估与安慰剂相比，单滴萘非那酮是否能减轻玻璃体内注射后的眼部不适。
方法
120例接受贝伐单抗或雷珠单抗玻璃体内注射的患者，采用前瞻性、双盲、随机对照设计，在注射后接受一滴萘非那酮或安慰剂（思然倍润）。患者在术后1小时、6小时和24小时对疼痛程度进行0至3级评分（无疼痛、轻度疼痛、中度疼痛、重度疼痛）。
结果
与安慰剂相比，注射后6小时萘非那酮使注射后疼痛有统计学意义的减轻（0.8±0.6[标准差]对1.3±0.8，P<0.001），1小时（1.1±0.7对1.3±0.7，P=0.12）和24小时（0.3±0.5对0.5±0.6，P=0.15）有相似趋势。
结论
单滴萘非那酮可有效减轻玻璃体内注射后的不适。
Zotero 插件